Evaluation of treatment with progesterone in controlled ovarian stimulation for patients undergoing IVF/ICSI cycles to prevent ovulation: a randomized clinical trial

Evaluation of treatment with progesterone in controlled ovarian stimulation for patients undergoing IVF/ICSI cycles to prevent ovulation: a randomized clinical trial - MPA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035469

Enrollment

Registered

2019-01-07

Start date

2019-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

10mg of MPA (medroxyprogesterone) oral intake daily for 10 days 0.25mg of GnRHantagonist injection subcutaneously daily for 1 to 3 days

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who will undergo IVF treatments by controlled ovarian hyperstimulation with AMH level 1 ng/ml or higher

Exclusion criteria

Exclusion criteria: 1 Patients with ovulatory disturbance caused by reduced hypothalamic or pituitary activity 2 Patients who can not use GnRH-agonist nasal spray for triggering final oocyte maturation

Design outcomes

Primary

Measure	Time frame
the incidence of ovulation before oocyte retrieval	—

Countries

Japan

Contacts

Public ContactEri Okamoto

Hanabusa Womens' clinic Docter

okamoto@hanabusaclinic.com078-392-8723

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026